eMedicine Specialties > Neurology > Neuro-oncology

Ependymoma

Author: Subrata Ghosh, MD, MBBS, MS, Staff Physician, Assistant Professor of Neurosurgery, Baylor College of Medicine, Houston, Division of Neurosurgery, St. Luke's Episcopal Hospital, Texas Medical Center, Houston, TX
Coauthor(s): Draga Jichici, BSc, MD, FRCP, Associate Clinical Professor, Department of Medicine, Division of Neurology and Critical Care Medicine, McMaster University, Canada
Contributor Information and Disclosures

Updated: Jun 1, 2009

Introduction

Background

Ependymomas are neoplasms of ependymal cells that occur throughout the entire neuraxis in association with the lining of the cerebral ventricles and central canal of the spinal cord.

Pathophysiology

Ependymomas occur most commonly in the intracranial and intraspinal areas, with lesions rarely occurring in the sacral area. Other unusual ectopic sites of ependymoma are the mediastinum, ovary, and broad ligament. In general, the anatomic location determines the pathophysiological manifestations of the tumor. Supratentorial tumors present with mass effect, focal neurological signs, and occasional obstruction of ventricular outflow. The relationship with the ventricular system is more apparent in tumors of the posterior fossa (mostly of the fourth ventricle), which usually present with obstructive hydrocephalus with or without signs of brain stem compression.

Frequency

United States

Ependymomas are infrequent tumors, representing 2-8% of all brain tumors. However, ependymomas are the third most common brain tumor in children (8-12%) with up to 30% occurring in children younger than 3 years. Half of the ependymomas occur in the first 2 decades of life; two-thirds are located in the posterior fossa (>90% are in the fourth ventricle). Interestingly, despite their overall low frequency, ependymomas are the most frequent neuroepithelial tumors of the spinal cord.

Mortality/Morbidity

From the biological perspective, ependymomas do not usually proliferate rapidly, are not invasive, and usually do not metastasize.1 The associated morbidity can mainly be accounted for by the local space-occupying effects of the tumor. In unusual cases, the risk of sudden death from large intracranial ependymomas results from increased intracranial pressure secondary to obstructive hydrocephalus.

Race

No race predilection is reported.

Sex

No sex predilection is reported.

Age

Peak age at presentation ranges from 7 weeks to 16 years with a mean of 3.7 years. A second, lower peak age of presentation occurs in the third decade of life.

Clinical

History

Presenting features are insidious and progressive in nature.

  • Nausea and vomiting (80%) is the most common presenting symptom, secondary to increased intracranial pressure.
  • Headache (60%), due to the local effect of pressure or increased intracranial pressure, is usually worse in the morning.
  • Change in behavior (50%) includes lethargy, irritability, diminished social interaction, and loss of appetite (prevalent in younger children).
  • Difficulty with balance (30%) reflects cerebellar involvement or mass effect.

Physical

  • Papilledema (60%)
  • Ataxia (45%)
  • Nystagmus with or without gaze palsy (40%)
  • Lower cranial nerve palsies (10%)
  • Apraxia or hemiparesis (20%)
  • Increase in head circumference in children younger than 2 years (10%)

Causes

No particular genetic or molecular marker or familial predisposition has been identified for this tumor type. In one series, only a few ependymomas were reported to be hyperdiploid or tetraploid.

  • Other diagnostic considerations:
    • Meningitis
    • Encephalitis
    • Other brain tumors (astrocytoma, medulloblastoma, oligodendroglioma)
    • Meningitis and encephalitis can be readily differentiated by their more abrupt onset, associated fever, or signs of meningeal irritation.
    • Differentiation from other types of brain tumors (astrocytoma, medulloblastoma, oligodendroglioma) is radiological and pathological.

More on Ependymoma

Overview: Ependymoma
Differential Diagnoses & Workup: Ependymoma
Treatment & Medication: Ependymoma
Follow-up: Ependymoma
Multimedia: Ependymoma
References
[ CLOSE WINDOW ]

References

  1. Nazar GB, Hoffman HJ, Becker LE, et al. Infratentorial ependymomas in childhood: prognostic factors and treatment. J Neurosurg. Mar 1990;72(3):408-17. [Medline].

  2. Ernestus RI, Schroder R, Stutzer H, Klug N. The clinical and prognostic relevance of grading in intracranial ependymomas. Br J Neurosurg. Oct 1997;11(5):421-8. [Medline].

  3. Kleihues P, Burger PC, Scheithauer BW. The new WHO classification of brain tumours. Brain Pathol. Jul 1993;3(3):255-68. [Medline].

  4. McLaughlin MP, Marcus RB, Buatti JM, et al. Ependymoma: results, prognostic factors and treatment recommendations. Int J Radiat Oncol Biol Phys. Mar 1 1998;40(4):845-50. [Medline].

  5. Moynihan TJ. Ependymal tumors. Curr Treat Options Oncol. Dec 2003;4(6):517-23. [Medline].

  6. Bhattacharjee MB, Armstrong DD, Vogel H, Cooley LD. Cytogenetic analysis of 120 primary pediatric brain tumors and literature review. Cancer Genet Cytogenet. Aug 1997;97(1):39-53. [Medline].

  7. Bigner SH, McLendon RE, Fuchs H, et al. Chromosomal characteristics of childhood brain tumors. Cancer Genet Cytogenet. Sep 1997;97(2):125-34. [Medline].

  8. Graham DI, Lantos PL, eds. Greenfield's Neuropathology. 6th ed. Arnold Press; 1997:636-44.

  9. Kaye AH, Laws E Jr, eds. Brain Tumors: An Encyclopedic Approach. First ed. Churchill Livingstone; 1997:493-504.

  10. Kleihues P et al. Pathology & Genetics. Tumors of the Nervous System. International Agency for Research on Cancer (IARC)/World Health Organization. 1997;96-109.

  11. Kun LE. Brain tumors. Challenges and directions. Pediatr Clin North Am. Aug 1997;44(4):907-17. [Medline].

  12. Osborn AG. Diagnostic Neuroradiology: A Text and Atlas. First ed. Mosby; 1994:566-70.

  13. Russell DS, et al. Pathology of Tumors of the Nervous System. 4th ed. Arnold Press; 1977:203-26.

[ CLOSE WINDOW ]

Further Reading

[ CLOSE WINDOW ]

Keywords

ependymal cells neoplasms, hydrocephalus, neuroepithelial tumor of the spinal cord, hyperdiploid tumor, tetraploid tumor, meningitis, encephalitis, astrocytoma, medulloblastoma, oligodendroglioma, brain tumor

[ CLOSE WINDOW ]

Contributor Information and Disclosures

Author

Subrata Ghosh, MD, MBBS, MS, Staff Physician, Assistant Professor of Neurosurgery, Baylor College of Medicine, Houston, Division of Neurosurgery, St. Luke's Episcopal Hospital, Texas Medical Center, Houston, TX
Subrata Ghosh, MD, MBBS, MS is a member of the following medical societies: American Association of Neurological Surgeons, American Medical Association, Congress of Neurological Surgeons, and Texas Medical Association
Disclosure: Nothing to disclose.

Coauthor(s)

Draga Jichici, BSc, MD, FRCP, Associate Clinical Professor, Department of Medicine, Division of Neurology and Critical Care Medicine, McMaster University, Canada
Disclosure: Nothing to disclose.

Medical Editor

Rodrigo O Kuljis, MD, Esther Lichtenstein Professor of Psychiatry and Neurology, Director, Division of Cognitive and Behavioral Neurology, Department of Neurology, University of Miami School of Medicine
Rodrigo O Kuljis, MD is a member of the following medical societies: American Academy of Neurology and Society for Neuroscience
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: Nothing to disclose.

Managing Editor

Jorge Kattah, MD, Head, Program Director, Professor, Department of Neurology, University of Illinois College of Medicine at Peoria
Jorge Kattah, MD is a member of the following medical societies: American Academy of Neurology, American Neurological Association, and New York Academy of Sciences
Disclosure: Biogen Honoraria Consulting; Bayer Corporation Honoraria Consulting

CME Editor

Matthew J Baker, MD, Consulting Staff, Collier Neurologic Specialists, Naples Community Hospital
Matthew J Baker, MD is a member of the following medical societies: American Academy of Neurology
Disclosure: Nothing to disclose.

Chief Editor

Stephen A Berman, MD, PhD, Professor, Department of Internal Medicine, Section of Neurology, Dartmouth Medical School; Chief, Neurology Service, White River Junction Veterans Medical Center
Stephen A Berman, MD, PhD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Neurology, and Phi Beta Kappa
Disclosure: Nothing to disclose.

RELATED MEDSCAPE ARTICLES
Articles
 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.